The company's most well-known product within the industry is the CorPath GRX System, a second-generation robotics solution used by interventional cardiologists during PCI and other interventional procedures.

The study, published in JACC: Cardiovascular Interventions, focused on data from more than 3,500 TAVR patients. 

A comparative meta-analysis found similar procedural outcomes, but higher 90-day mortality—partially attributable to a higher rate of comorbidities.

Even after adjusting for factors such as income, comorbidities and stroke severity indicators, a prolonged length of stay was more common for Black patients.

AVS, a Michigan-based medical device company, has said the funding will help accelerate research on its new Pulse P-IVL system. One clinical trial is already underway. 

The single-dose gene therapy can help patients reduce their risk of bleeding events and discontinue factor IX prophylaxis therapy.